Horizon Therapeutics Public Stock Price Target and Analyst Ratings (NASDAQ:HZNP)

Analyst Price Target for HZNP

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$101.89

▲ +12.08% Upside Potential

This price target is based on 8 analysts offering 12 month price targets for Horizon Therapeutics Public in the last 3 months. The average price target is $101.89, with a high forecast of $120.00 and a low forecast of $85.00. The average price target represents a 12.08% upside from the last price of $90.91.

Buy

The current consensus among 8 contributing investment analysts is to buy stock in Horizon Therapeutics Public. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
9 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

9/6/2019

0 strong buy ratings
11 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

12/5/2019

0 strong buy ratings
11 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

3/4/2020

0 strong buy ratings
11 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

6/2/2020

0 strong buy ratings
11 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

8/31/2020

0 strong buy ratings
10 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

11/29/2020

0 strong buy ratings
8 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/28/2021

0 strong buy ratings
8 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/27/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
2/17/2021	Jefferies Financial Group	Boost Price Target		$103.00 ➝ $120.00	Low	i
2/9/2021	Bank of America	Reiterated Rating	Buy	$100.00	Low	i Rating by Jason Gerberry at Bank of America Co.
11/3/2020	BMO Capital Markets	Boost Price Target	Outperform	$105.00 ➝ $110.00	Medium	i
9/9/2020	JPMorgan Chase & Co.	Initiated Coverage	Overweight	$110.00	High	i
8/27/2020	Citigroup	Initiated Coverage	Buy	$112.00	Medium	i
8/17/2020	Bank of America	Boost Price Target	Buy	$92.00 ➝ $95.00	Low	i Rating by Jason Gerberry at Bank of America Co.
8/10/2020	Morgan Stanley	Boost Price Target	Overweight	$70.00 ➝ $90.00	Low	i
8/6/2020	Guggenheim	Boost Price Target		$64.00 ➝ $100.00	High	i
8/6/2020	BMO Capital Markets	Boost Price Target	Outperform	$70.00 ➝ $105.00	High	i
8/3/2020	Stifel Nicolaus	Boost Price Target		$60.00 ➝ $85.00	Low	i Rating by Annabel Samimy at Stifel Nicolaus
7/31/2020	Morgan Stanley	Boost Price Target	Overweight	$50.00 ➝ $70.00	Low	i
7/22/2020	Piper Sandler	Boost Price Target	Overweight	$61.00 ➝ $90.00	Low	i Rating by David Amsellem at Piper Sandler
7/16/2020	Guggenheim	Boost Price Target		$50.00 ➝ $64.00	Low	i
6/5/2020	Piper Sandler	Reiterated Rating	Buy	$61.00	Medium	i Rating by David Amsellem at Piper Sandler
5/29/2020	Stifel Nicolaus	Boost Price Target		$50.00 ➝ $60.00	High	i Rating by Annabel Samimy at Stifel Nicolaus
5/26/2020	Bank of America	Boost Price Target	Buy	$52.00 ➝ $57.00	Medium	i Rating by Jason Gerberry at Bank of America Co.
5/21/2020	Piper Sandler	Boost Price Target	Overweight	$50.00 ➝ $61.00	Medium	i
5/8/2020	Morgan Stanley	Boost Price Target	Overweight	$39.00 ➝ $50.00	High	i
4/28/2020	Jefferies Financial Group	Boost Price Target	Buy	$47.00 ➝ $51.00	High	i
4/14/2020	Piper Sandler	Lower Price Target	Overweight	$46.00 ➝ $44.00	High	i
4/8/2020	Stifel Nicolaus	Reiterated Rating	Buy	$45.00	Low	i Rating by Annabel Samimy at Stifel Nicolaus
4/2/2020	Morgan Stanley	Lower Price Target	Overweight	$42.00 ➝ $39.00	High	i
3/23/2020	Bank of America	Lower Price Target	Buy	$45.00 ➝ $42.00	Low	i Rating by Jason Gerberry at Bank of America Co.
2/25/2020	Bank of America	Reiterated Rating	Buy	$45.00	High	i Rating by Jason Gerberry at Bank of America Co.
1/22/2020	BMO Capital Markets	Boost Price Target	Outperform	$40.00 ➝ $46.00	Low	i
1/14/2020	JMP Securities	Boost Price Target	Outperform	$47.00	Medium	i
1/8/2020	The Goldman Sachs Group	Initiated Coverage	Neutral	$35.00	Low	i
12/24/2019	Piper Jaffray Companies	Reiterated Rating	Buy	$36.00 ➝ $49.00	Low	i Rating by David Amsellem at Piper Jaffray Companies
12/16/2019	Morgan Stanley	Boost Price Target	Overweight	$32.00 ➝ $38.00	High	i
12/16/2019	Jefferies Financial Group	Boost Price Target	Buy	$35.00 ➝ $40.00	High	i
12/16/2019	Stifel Nicolaus	Boost Price Target	Buy	$35.00 ➝ $40.00	High	i Rating by Annabel Samimy at Stifel Nicolaus
12/16/2019	BMO Capital Markets	Boost Price Target	Outperform	$36.00 ➝ $40.00	High	i
11/8/2019	Cantor Fitzgerald	Boost Price Target	Overweight	$32.00 ➝ $36.00	Low	i
9/26/2019	Bank of America	Initiated Coverage	Buy	$34.00	High	i
9/13/2019	Stifel Nicolaus	Set Price Target	Buy	$35.00	Low	i Rating by Annabel Samimy at Stifel Nicolaus
9/12/2019	Guggenheim	Initiated Coverage	Buy	$36.00	Low	i
8/26/2019	Piper Jaffray Companies	Set Price Target	Buy	$33.00	Low	i Rating by David Amsellem at Piper Jaffray Companies
8/14/2019	BMO Capital Markets	Upgrade	Market Perform ➝ Outperform	$29.00 ➝ $36.00	Low	i Rating by Gary Nachman at BMO Capital Markets
8/7/2019	Cowen	Set Price Target	Buy	$35.00	Medium	i Rating by Ken Cacciatore at Cowen Inc
5/8/2019	Mizuho	Set Price Target	Hold	$27.00	Low	i Rating by Irina Rivkind Koffler at Mizuho
5/1/2019	Citigroup	Upgrade	Neutral ➝ Buy	$21.00 ➝ $32.00	Medium	i
4/4/2019	Piper Jaffray Companies	Set Price Target	Buy	$33.00	Low	i Rating by David Amsellem at Piper Jaffray Companies
4/4/2019	BMO Capital Markets	Boost Price Target	Market Perform	$29.00	Medium	i
4/2/2019	Cantor Fitzgerald	Boost Price Target	Overweight ➝ Buy	$26.00 ➝ $32.00	Medium	i
3/8/2019	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$32.00	Low	i
3/1/2019	JMP Securities	Boost Price Target	Outperform	$26.00 ➝ $38.00	High	i Rating by Donald Ellis at JMP Securities
3/1/2019	Jefferies Financial Group	Boost Price Target	Positive ➝ Buy	$34.00	High	i
3/1/2019	Mizuho	Reiterated Rating	Positive ➝ Neutral	$27.00	High	i
2/28/2019	Cowen	Set Price Target	Buy	$33.00	Medium	i Rating by Ken Cacciatore at Cowen Inc
2/7/2019	Mizuho	Reiterated Rating	Hold	$21.00	Low	i
1/14/2019	Piper Jaffray Companies	Set Price Target	Buy	$26.00	Low	i Rating by David Amsellem at Piper Jaffray Companies
11/15/2018	Mizuho	Downgrade	Buy ➝ Neutral	$25.00 ➝ $21.00	High	i
11/7/2018	Mizuho	Reiterated Rating	Buy	$25.00	High	i
11/1/2018	Stifel Nicolaus	Boost Price Target	Buy	$25.00 ➝ $35.00	High	i
10/23/2018	Cowen	Set Price Target	Buy	$25.00	High	i Rating by Ken Cacciatore at Cowen Inc
10/18/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$21.00	Low	i Rating by Louise Chen at Cantor Fitzgerald
10/16/2018	Mizuho	Reiterated Rating	Buy		High	i
10/6/2018	JMP Securities	Set Price Target	Buy	$22.00	High	i Rating by Donald Ellis at JMP Securities
10/4/2018	The Goldman Sachs Group	Set Price Target	Buy	$26.00	Low	i Rating by Dana Flanders at The Goldman Sachs Group, Inc.
9/24/2018	Piper Jaffray Companies	Set Price Target	Buy	$25.00	Medium	i Rating by David Amsellem at Piper Jaffray Companies
9/17/2018	Piper Jaffray Companies	Set Price Target	Buy	$25.00	High	i Rating by David Amsellem at Piper Jaffray Companies
9/13/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$21.00	Low	i Rating by Louise Chen at Cantor Fitzgerald
8/17/2018	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$16.00 ➝ $24.00	Low	i
8/9/2018	Jefferies Financial Group	Boost Price Target	Buy ➝ Buy	$21.00 ➝ $23.00	High	i
8/9/2018	Cowen	Reiterated Rating	Buy	$25.00	High	i
8/9/2018	Piper Jaffray Companies	Reiterated Rating	Buy	$25.00	High	i
8/8/2018	Mizuho	Reiterated Rating	Buy	$18.00	High	i
8/8/2018	Cantor Fitzgerald	Set Price Target	Buy	$21.00	Low	i Rating by Louise Chen at Cantor Fitzgerald
8/6/2018	BMO Capital Markets	Downgrade	Outperform ➝ Market Perform	$18.00 ➝ $18.00	Low	i
7/25/2018	Cantor Fitzgerald	Boost Price Target	Overweight	$21.00	High	i Rating by Louise Chen at Cantor Fitzgerald
6/27/2018	Citigroup	Downgrade	Buy ➝ Neutral		Low	i
6/18/2018	Stifel Nicolaus	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00	Low	i
5/9/2018	Cantor Fitzgerald	Set Price Target	Buy	$17.00	High	i Rating by Louise Chen at Cantor Fitzgerald
5/7/2018	Mizuho	Reiterated Rating	Buy	$18.00	Low	i
4/15/2018	Cantor Fitzgerald	Set Price Target	Buy	$17.00	High	i Rating by Louise Chen at Cantor Fitzgerald
3/14/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$17.00	Low	i Rating by Louise Chen at Cantor Fitzgerald
3/2/2018	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$14.00 ➝ $16.00	High	i
3/1/2018	Piper Jaffray Companies	Reiterated Rating	Buy	$22.00	High	i Rating by David Amsellem at Piper Jaffray Companies
3/1/2018	Cowen	Reiterated Rating	Buy	$24.00	High	i
3/1/2018	UBS Group	Set Price Target	Buy	$20.00	Medium	i Rating by Marc Goodman at UBS Group AG
2/28/2018	Cantor Fitzgerald	Set Price Target	Buy	$17.00	Medium	i Rating by Louise Chen at Cantor Fitzgerald
1/12/2018	Mizuho	Upgrade	Neutral ➝ Buy	$12.00 ➝ $18.00	Medium	i
1/8/2018	Cantor Fitzgerald	Set Price Target	Buy	$17.00	Medium	i Rating by Louise Chen at Cantor Fitzgerald
12/27/2017	Cantor Fitzgerald	Set Price Target	Buy	$17.00	Low	i Rating by Louise Chen at Cantor Fitzgerald
12/1/2017	Cantor Fitzgerald	Set Price Target	Buy	$17.00	Low	i Rating by Louise Chen at Cantor Fitzgerald
11/30/2017	UBS Group	Set Price Target	Buy	$16.00 ➝ $20.00	High	i Rating by Marc Goodman at UBS Group AG
11/7/2017	Jefferies Financial Group	Boost Price Target	Buy	$16.00 ➝ $21.00	N/A	i
10/22/2017	Stifel Nicolaus	Reiterated Rating	Buy	$20.00	N/A	i Rating by Annabel Samimy at Stifel Nicolaus
10/15/2017	Piper Jaffray Companies	Set Price Target	Buy	$18.00	N/A	i Rating by David Amsellem at Piper Jaffray Companies
10/5/2017	Jefferies Financial Group	Reiterated Rating	Buy	$16.00	N/A	i Rating by David Steinberg at Jefferies Financial Group Inc.
9/28/2017	Cowen	Reiterated Rating	Buy		Low	i Rating by Ken Cacciatore at Cowen Inc
9/28/2017	The Goldman Sachs Group	Initiated Coverage	Buy ➝ Buy	$16.00	Medium	i
9/27/2017	Jefferies Financial Group	Reiterated Rating	Buy	$16.00	Medium	i Rating by David Steinberg at Jefferies Financial Group Inc.
9/26/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$17.00	Low	i Rating by Louise Chen at Cantor Fitzgerald
9/11/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$17.00	High	i Rating by Louise Chen at Cantor Fitzgerald
9/10/2017	Piper Jaffray Companies	Set Price Target	Buy	$18.00	Low	i Rating by David Amsellem at Piper Jaffray Companies
8/28/2017	Mizuho	Reiterated Rating	Hold	$9.00 ➝ $12.00	Medium	i
8/17/2017	Cantor Fitzgerald	Set Price Target	Buy	$17.00	Medium	i Rating by Louise Chen at Cantor Fitzgerald
8/10/2017	BMO Capital Markets	Reiterated Rating	Outperform	$17.00 ➝ $18.00	High	i
8/9/2017	Cantor Fitzgerald	Reiterated Rating	Overweight	$13.00 ➝ $17.00	High	i Rating by Louise Chen at Cantor Fitzgerald
8/9/2017	Mizuho	Reiterated Rating	Neutral	$10.00 ➝ $9.00	Low	i
8/8/2017	UBS Group	Set Price Target	Buy	$16.00	High	i Rating by Marc Goodman at UBS Group AG
8/7/2017	Piper Jaffray Companies	Set Price Target	Buy	$18.00	High	i Rating by David Amsellem at Piper Jaffray Companies
7/31/2017	Cantor Fitzgerald	Set Price Target	Buy	$13.00	High	i
7/28/2017	BMO Capital Markets	Reiterated Rating	Buy	$17.00	High	i
7/25/2017	Piper Jaffray Companies	Set Price Target	Buy	$17.00	High	i Rating by David Amsellem at Piper Jaffray Companies
7/14/2017	Jefferies Financial Group	Reiterated Rating	Buy	$14.00	Low	i Rating by David Steinberg at Jefferies Financial Group Inc.
6/16/2017	Cantor Fitzgerald	Initiated Coverage	Overweight ➝ Overweight	$13.00	Low	i
6/7/2017	UBS Group	Set Price Target	Buy	$22.00 ➝ $16.00	N/A	i Rating by Marc Goodman at UBS Group AG
5/9/2017	Citigroup	Lower Price Target	Buy	$20.00 ➝ $13.00	Medium	i
5/9/2017	Jefferies Financial Group	Set Price Target	Buy	$26.00 ➝ $14.00	Low	i Rating by David Steinberg at Jefferies Financial Group Inc.
5/9/2017	Stifel Nicolaus	Reiterated Rating	Buy ➝ Buy	$35.00 ➝ $20.00	High	i
5/9/2017	Cowen	Set Price Target	Outperform	$42.00 ➝ $20.00	Medium	i
5/9/2017	Mizuho	Downgrade	Buy ➝ Neutral	$22.00 ➝ $10.00	High	i
5/9/2017	BMO Capital Markets	Reiterated Rating	Buy	$24.00 ➝ $17.00	High	i Rating by Gary Nachman at BMO Capital Markets
4/12/2017	Jefferies Financial Group	Set Price Target	Buy	$26.00	Low	i Rating by David Steinberg at Jefferies Financial Group Inc.
3/29/2017	BMO Capital Markets	Reiterated Rating	Buy	$24.00	Low	i Rating by Gary Nachman at BMO Capital Markets
3/24/2017	Piper Jaffray Companies	Lower Price Target	Overweight	$32.00 ➝ $30.00	Low	i
2/28/2017	Mizuho	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $22.00	N/A	i
2/28/2017	Morgan Stanley	Reiterated Rating	Equal Weight	$20.00	N/A	i Rating by david risinger at Morgan Stanley
2/27/2017	Guggenheim	Initiated Coverage	Buy	$30.00	N/A	i
2/22/2017	Mizuho	Reiterated Rating	Buy	$25.00	N/A	i
12/18/2016	Jefferies Financial Group	Set Price Target	Buy	$26.00	N/A	i Rating by David Steinberg at Jefferies Financial Group Inc.
12/16/2016	Mizuho	Upgrade	Neutral ➝ Buy	$14.00 ➝ $25.00	N/A	i
12/9/2016	Mizuho	Downgrade	Buy ➝ Neutral	$30.00 ➝ $14.00	N/A	i
12/8/2016	UBS Group	Set Price Target	Buy	$23.00	N/A	i Rating by Marc Goodman at UBS Group AG
12/8/2016	Jefferies Financial Group	Set Price Target	Buy	$26.00	N/A	i Rating by David Steinberg at Jefferies Financial Group Inc.
12/8/2016	BMO Capital Markets	Reiterated Rating	Outperform	$29.00 ➝ $24.00	N/A	i
12/1/2016	Mizuho	Reiterated Rating	Buy		N/A	i
11/28/2016	BMO Capital Markets	Reiterated Rating	Outperform	$29.00	N/A	i
11/28/2016	Citigroup	Upgrade	Neutral ➝ Buy		N/A	i
11/8/2016	Mizuho	Boost Price Target	Buy	$29.00 ➝ $30.00	N/A	i
10/31/2016	Mizuho	Lower Price Target	Buy	$33.00 ➝ $29.00	N/A	i Rating by Irina Rivkind Koffler at Mizuho
10/12/2016	The Goldman Sachs Group	Set Price Target	Buy	$26.00	N/A	i Rating by Stephan Stewart at The Goldman Sachs Group, Inc.
10/11/2016	Mizuho	Reiterated Rating	Buy	$33.00	N/A	i Rating by Irina Rivkind Koffler at Mizuho
9/29/2016	Mizuho	Reiterated Rating	Buy		N/A	i Rating by Irina Rivkind Koffler at Mizuho
9/28/2016	Morgan Stanley	Reiterated Rating	Hold	$24.00	N/A	i Rating by david risinger at Morgan Stanley
9/27/2016	The Goldman Sachs Group	Reiterated Rating	Buy	$27.00	N/A	i
9/13/2016	BMO Capital Markets	Reiterated Rating	Outperform	$30.00	N/A	i
9/13/2016	Mizuho	Boost Price Target	Buy	$30.00 ➝ $33.00	N/A	i Rating by Irina Rivkind Koffler at Mizuho
9/12/2016	Morgan Stanley	Set Price Target	Hold	$24.00	N/A	i Rating by david risinger at Morgan Stanley
9/12/2016	Brean Capital	Reiterated Rating	Buy	$32.00	N/A	i Rating by Difei Yang at Brean Capital
9/12/2016	Cowen	Reiterated Rating	Outperform ➝ Outperform	$42.00	N/A	i Rating by Ken Cacciatore at Cowen Inc
9/8/2016	The Goldman Sachs Group	Reiterated Rating	Buy	$27.00	N/A	i
9/8/2016	Jefferies Financial Group	Reiterated Rating	Buy		N/A	i Rating by david steinberg at Jefferies Financial Group Inc.
8/23/2016	Guggenheim	Reiterated Rating	Buy	$30.00	N/A	i Rating by Louise Chen at Guggenheim
8/10/2016	Mizuho	Reiterated Rating	Buy	$24.00 ➝ $30.00	N/A	i Rating by Irina Rivkind Koffler at Mizuho
8/10/2016	BMO Capital Markets	Reiterated Rating	Outperform	$29.00 ➝ $30.00	N/A	i
8/10/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$34.00 ➝ $33.00	N/A	i Rating by David Amsellem at Piper Jaffray Companies
8/9/2016	Brean Capital	Reiterated Rating	Buy	$30.00	N/A	i Rating by Difei Yang at Brean Capital
8/9/2016	Citigroup	Boost Price Target	Neutral	$18.00 ➝ $21.00	N/A	i
8/9/2016	UBS Group	Reiterated Rating	Buy	$24.00	N/A	i Rating by Marc Goodman at UBS Group AG
8/4/2016	Jefferies Financial Group	Reiterated Rating	Buy	$27.00	N/A	i Rating by David Steinberg at Jefferies Financial Group Inc.
8/3/2016	BMO Capital Markets	Reiterated Rating	Outperform	$29.00	N/A	i
8/3/2016	Mizuho	Reiterated Rating	Outperform	$24.00	N/A	i Rating by Irina Rivkind Koffler at Mizuho
8/2/2016	Brean Capital	Reiterated Rating	Buy		N/A	i Rating by Difei Yang at Brean Capital
8/1/2016	Guggenheim	Reiterated Rating	Buy	$30.00	N/A	i
7/14/2016	Brean Capital	Reiterated Rating	Buy	$30.00	N/A	i Rating by Difei Yang at Brean Capital
7/11/2016	Morgan Stanley	Upgrade	Underweight ➝ Equal Weight	$24.00	N/A	i
7/6/2016	Stifel Nicolaus	Reiterated Rating	Buy	$45.00	N/A	i Rating by Annabel Samimy at Stifel Nicolaus
6/28/2016	BMO Capital Markets	Initiated Coverage	Outperform	$29.00	N/A	i
6/6/2016	The Goldman Sachs Group	Initiated Coverage	Buy	$24.00	N/A	i
6/1/2016	Citigroup	Initiated Coverage	Neutral		N/A	i
5/20/2016	UBS Group	Reiterated Rating	Buy	$24.00	N/A	i Rating by Marc Goodman at UBS Group AG
5/10/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$44.00 ➝ $34.00	N/A	i Rating by David Amsellem at Piper Jaffray Companies
5/10/2016	Guggenheim	Reiterated Rating	Buy		N/A	i Rating by Louise Chen at Guggenheim
5/10/2016	Mizuho	Reiterated Rating	Buy	$25.00 ➝ $24.00	N/A	i Rating by Irina Rivkind Koffler at Mizuho
5/3/2016	Mizuho	Reiterated Rating	Buy	$34.00 ➝ $25.00	N/A	i Rating by Irina Rivkind Koffler at Mizuho
4/25/2016	Citigroup	Lower Price Target	Neutral	$21.00 ➝ $18.00	N/A	i
4/19/2016	UBS Group	Reiterated Rating	Buy		N/A	i Rating by Marc Goodman at UBS Group AG
4/16/2016	Brean Capital	Reiterated Rating	Buy	$32.00 ➝ $30.00	N/A	i Rating by Difei Yang at Brean Capital
4/13/2016	UBS Group	Reiterated Rating	Buy	$39.00 ➝ $24.00	N/A	i Rating by Marc Goodman at UBS Group AG
4/13/2016	Piper Jaffray Companies	Reiterated Rating	Buy	$44.00	N/A	i Rating by David Amsellem at Piper Jaffray Companies
4/12/2016	Mizuho	Reiterated Rating	Buy	$34.00	N/A	i Rating by Irina Rivkind Koffler at Mizuho
4/12/2016	Stifel Nicolaus	Reiterated Rating	Buy		N/A	i Rating by Annabel Samimy at Stifel Nicolaus
4/2/2016	Cowen	Reiterated Rating	Buy		N/A	i Rating by Ken Cacciatore at Cowen Inc
3/3/2016	Brean Capital	Reiterated Rating	Buy	$32.00	N/A	i Rating by Difei Yang at Brean Capital
3/3/2016	Jefferies Financial Group	Reiterated Rating	Buy	$31.00	N/A	i Rating by David Steinberg at Jefferies Financial Group Inc.
3/2/2016	UBS Group	Reiterated Rating	Buy		N/A	i Rating by Marc Goodman at UBS Group AG
2/29/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$46.00 ➝ $44.00	N/A	i Rating by David Amsellem at Piper Jaffray Companies
2/27/2016	Mizuho	Reiterated Rating	Buy	$36.00 ➝ $34.00	N/A	i Rating by Irina Rivkind Koffler at Mizuho

(Data available from 2/27/2016 forward)

Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing of medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of rheumatoid arthritis (RA), polymyalgia rheumatic, systemic lupus erythematosus, and various other indications; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. The company also offers PENNSAID 2% that is indicated for the treatment of pain of osteoarthritis (OA) of the knees; DUEXIS for the relief of signs and symptoms of RA and OA, and to decrease the risk of developing upper-GI ulcers; and VIMOVO for the relief of signs and symptoms of OA, RA, and ankylosing spondylitis to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. It has collaboration agreements with Lupus Research and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Today's Range

Now: $90.91

$89.77

$93.30

50 Day Range

MA: $82.35

$71.83

$95.48

52 Week Range

Now: $90.91

$23.81

$96.54

Volume

3,106,805 shs

Average Volume

2,095,738 shs

Market Capitalization

$20.06 billion

P/E Ratio

24.84

Dividend Yield

N/A

Beta

1.15

Frequently Asked Questions

What sell-side analysts currently cover shares of Horizon Therapeutics Public?

The following Wall Street analysts have issued reports on Horizon Therapeutics Public in the last twelve months: Bank of America Co., BMO Capital Markets, Citigroup Inc., Guggenheim, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, Stifel Nicolaus, and Zacks Investment Research.
View the latest analyst ratings for HZNP.

What is the current price target for Horizon Therapeutics Public?

9 Wall Street analysts have set twelve-month price targets for Horizon Therapeutics Public in the last year. Their average twelve-month price target is $101.89, suggesting a possible upside of 12.1%. Jefferies Financial Group Inc. has the highest price target set, predicting HZNP will reach $120.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $85.00 for Horizon Therapeutics Public in the next year.
View the latest price targets for HZNP.

What is the current consensus analyst rating for Horizon Therapeutics Public?

Horizon Therapeutics Public currently has 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HZNP will outperform the market and that investors should add to their positions of Horizon Therapeutics Public.
View the latest ratings for HZNP.

What other companies compete with Horizon Therapeutics Public?

Other companies that are similar to Horizon Therapeutics Public include Johnson & Johnson, Eli Lilly and, AbbVie, Pfizer, Merck & Co., Inc., Bristol-Myers Squibb, Zoetis, Royalty Pharma, Jazz Pharmaceuticals, Perrigo, Nektar Therapeutics, Pacira BioSciences, Corcept Therapeutics, Endo International and Supernus Pharmaceuticals.

How do I contact Horizon Therapeutics Public's investor relations team?

Horizon Therapeutics Public's physical mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. The biopharmaceutical company's listed phone number is 011-353-1772-2100 and its investor relations email address is [email protected] The official website for Horizon Therapeutics Public is www.horizontherapeutics.com.

NASDAQ:HZNP - Horizon Therapeutics Public Stock Price Target and Predictions

Analyst Price Target for HZNP

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Horizon Therapeutics Public?

What is the current price target for Horizon Therapeutics Public?

What is the current consensus analyst rating for Horizon Therapeutics Public?

What other companies compete with Horizon Therapeutics Public?

How do I contact Horizon Therapeutics Public's investor relations team?